Bavarian Nordic to discuss prostate cancer vaccines at upcoming symposium
PROSTVAC and MVA-BNPRO will be the subject of four clinical presentations to be delivered at the Genitourinary Cancers Symposium on February 14-16 in Orlando, Fla. Preliminary evaluations from the clinical studies on both drugs support further investigation of their beneficial effects on patients suffering from advanced prostate cancer.
Two of the posters will feature clinical data about PROSTVAC as a single therapy or when given in combination with a radiopharmaceutical. The third poster reviews the overall safety profile of poxviral vaccines from several clinical trials of PROSTVAC. The fourth poster will review the results of a Phase I dose escalation trial conducted on MVA-BNPRO.
"We are pleased that the clinical trial results of our immunotherapy candidates, including PROSTVAC, are being presented at a major medical conference, Anders Hedegaard, the president and CEO of Bavarian Nordic, said. "These preliminary data provide insight into the tolerability and unique profile of our poxviral platform for developing innovative cancer immunotherapies."
Bavarian Nordic said that full abstracts from all four studies will be made available online at the Genitourinary Cancers Symposium's website.